2024 Pharmaceutical Executive APEX Award Winners
Image Credit: Pharmaceutical Executive
It is with great pride that Pharmaceutical Executive presents the winners of this year’s APEX Awards. Decided by doctors, nurses and other health care professionals across the United States, this year’s ceremony included 30 industry leaders and globally recognized creative agencies.
This year’s winners were announced on November 13, 2024, at the New York Hilton Midtown in New York City.
The winners of the 2024 APEX Awards are as follows:
Aesthetics/Dermatology
Branded (FDA Regulated)
Company:
Sanofi & Regeneron
Agency:
Eversana InTouch
Campaign:
Eczema Skin Gallery
Disease Awareness
Company:
UCB
Agency:
Avant Healthcare
Campaign:
Make History (US HCP Campaign)
Cardiovascular
Branded (FDA Regulated)
Company:
AstraZeneca
Agency:
Addison Whitney
Campaign:
AmyLink / Amyloidosis Evidence Development Programme
Central Nervous System
Branded (FDA Regulated)
Company:
Lundbeck
Agency:
Eversana InTouch
Campaign:
Say "Yep" to Vypeti
Devices
Branded (FDA Regulated)
Company:
NeuroStar
Agency:
EvolveMKD
Campaign:
Breaking Barriers with Neurostar Depression Barometer
Disease Education/Awareness
Company:
Cerapedics Inc
Agency:
Scientific Global
Campaign:
FUSE: Fusion University for Surgical Excellence
Direct-to-Consumer
Branded (FDA Regulated)
Company:
Radius Health
Agency:
AbelsonTaylor
Campaign:
TYMLOS "Add to the Bone" Osteoporosis Consumer Campaign
Direct-to-Patient
Branded (FDA Regulated)
Company:
Arcutis
Agency:
AbelsonTaylor
Campaign:
The Cream That Can
Disease Education/Awareness
Company:
embecta
Agency:
Addison Whitney
Campaign:
From the Beginning | 2023 World Diabetes Day Campaign
Gastroenterology
Branded (FDA Regulated)
Company:
Nestle Health Science
Agency:
AbelsonTaylor
Campaign:
Toilet Monster
Immunology
Disease Education/Awareness
Company:
Pharvaris
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Pharvaris DeflateHAE Awards Video
Men’s Health
Branded (FDA Regulated)
Company:
Sanofi
Agency:
Saatchi & Saatchi Wellness
Campaign:
Your Lucky Day and a Half
Metabolic
Disease Education/Awareness
Company:
Acella Pharmaceuticals
Agency:
Scientific Global
Campaign:
Treating Hypothyroidism
Branded (FDA Regulated)
Company:
Novo Nordisk
Agency:
ConcentricLife
Campaign:
Believe On
Oncology
Disease Education/Awareness
Company:
Elevar Therapeutics
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Elevar uHCC Disease Awareness Campaign
Branded (FDA Regulated)
Company:
Manarini Stemline
Agency:
Biolumina
Campaign:
Picture What's Possible
Ophthalmology
Disease Education/Awareness
Company:
Kala Bio
Agency:
QBFox Healthcomm
Campaign:
Trail
Rare Disease
Branded (FDA Regulated)
Company:
Corcept Therapeutics
Agency:
Eversana InTouch
Campaign:
In the Clutches of Hypercortisolism
Disease Education/Awareness
Company:
Pharvaris
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Pharvaris DeflateHAE Awards Video
Respiratory
Branded (FDA Regulated)
Company:
Boehringer Ingelheim
Agency:
Confideo, LLC
Campaign:
OFEV Holographic Augmented Reality KOL Integrations
Surgery
Branded (FDA Regulated)
Company:
Vericel Corporation
Agency:
AbelsonTaylor
Campaign:
MACI: No Challenge, No Change
Disease Education/Awareness
Company:
Cerapedics Inc
Agency:
Scientific Global
Campaign:
FUSE: Fusion University for Surgical Excellence
Women’s Health
Branded (FDA Regulated)
Company:
Exeltis USA
Agency:
Spark Growth
Campaign:
#LetsLoveEveryBody
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
